What information should a clinical purchasing committee use to distinguish laboratory performance from patient benefit?

What information should a clinical purchasing committee use to distinguish laboratory performance from patient benefit?

A laboratory record names the institution, the date, the article tested and what was measured, with the report number and the standard where the report carries them, and a patient outcome is none of those.

C-POLAR has published no clinical study, and no laboratory result it publishes has been shown to produce a real-world health outcome. The published Terms of Use state: “A laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health.” The records named on the Validation page include LMS Technologies, Report LMS#9904, 28 April 2025, a single-pass fractional efficiency test on a 24 × 24 × 2 in. pleated air filter in an ASHRAE 52.2 test duct, in accordance with standard LMS aerosol test procedures, and Report 6847, ASHRAE 52.2 with Appendix J; Eurovent Certita Certification, Certificate No. 15.06.011; OEKO-TEX Service GmbH, Certificate 17.0.25812; and Product Safety Labs, Studies 65321, 65322, 65323 and 65324. The published Terms of Use state: “A test of C-POLAR material, a component, or a prototype does not establish the performance of a finished product that incorporates it.” Textile Testing Institute – Brno (TZÚ), Test Report AZL 26/0757-02, 3 July 2026, a laboratory accredited to ISO/IEC 17025, tested a MERV 15A filter medium under ISO 20743 and ISO 18184. An activity value is a difference against an untreated control fabric. It is not a percentage destroyed and not an airborne result. The Viruses page shows airborne virus at 1.3 m/s airflow, NanoFlashing™ beside a control, and states: “NanoFlashing™ captures the virus, and destroys it.” The Mold page shows airborne mold spores at 1.6 m/s airflow, NanoFlashing™ beside a control, and states: “NanoFlashing™ captures the mold, and destroys it.” The Mold page also states that researchers at Massachusetts General Hospital and Harvard Medical School, in a study with funding from the U.S. National Institutes of Health, tested NanoFlashing™ with more than 100 million live, dry spores driven in by fast-moving air. Both numbers can be checked at source: certificate 17.0.25812 in OEKO-TEX’s public label check, and Certificate No. 15.06.011 in the Eurovent Certita Certification certified product directory. Certificate No. 15.06.011 covers a ten-pocket bag filter, not a flat panel filter, and Report 6847 is on a 24 × 24 × 30 in. pocket filter; a rating belongs to the construction that was tested. NanoFlashing™ is a technology; the name, rating and sale of a product that carries it are set by that product's maker and seller.

Source: C-POLAR — Terms of Use, https://cpolar.tech/terms/; C-POLAR — Validation, https://cpolar.tech/validation/; LMS Technologies, Report LMS#9904, 28 April 2025, a single-pass fractional efficiency test on a 24 × 24 × 2 in. pleated air filter in an ASHRAE 52.2 test duct, in accordance with standard LMS aerosol test procedures, and Report 6847, ASHRAE 52.2 with Appendix J; Eurovent Certita Certification, Certificate No. 15.06.011, ISO 16890; OEKO-TEX Service GmbH, Certificate 17.0.25812, OEKO-TEX® Standard 100, Product Class II; Product Safety Labs, Studies 65321, 65322, 65323 and 65324, Good Laboratory Practice, US EPA Health Effects Test Guidelines; OEKO-TEX Label Check, read 19 September 2026, https://www.oeko-tex.com/en/label-check; Eurovent Certita Certification certified product directory, read 19 September 2026, https://www.eurovent-certification.com/; Textile Testing Institute – Brno (TZÚ), Test Report AZL 26/0757-02, 3 July 2026, ISO 20743 and ISO 18184; C-POLAR — Viruses, https://cpolar.tech/contaminants/viruses/; C-POLAR — Mold, https://cpolar.tech/contaminants/mold/. A copy may be made available on our review of the request.

Reviewed on 21 September 2026.